Category: News
New study by the Bioinformatics Unit of the Zanos lab suggests Metformin may offer better Alzheimer’s prevention potential in Diabetes patients compared with Semaglutide
No Comments
| News
The Zanos lab has recently published a preprint study examining the comparative effectiveness of diabetes medications in potentially reducing Alzheimer’s disease risk. The research was led by senior researchers Dr. Andrea Georgiou and Dr. Anna Onisiforou, key members of the Zanos laboratory team. The study, titled “Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s […]
Dr. Zanos presents our latest findings at University of Athens Neuroscience Seminar Series
Dr. Zanos, the Head of the Translational Neuropharmacology Lab, had the honor of presenting his research at the University of Athens as part of their Neuroscience Seminar Series. In his talk titled “Decoding ketamine: Neurobiological mechanisms underlying its rapid antidepressant efficacy,” Dr. Zanos shared his team’s findings on ketamine’s unique properties as an antidepressant. He […]
New Publication: (2R,6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement
The Zanos lab has just published a new study in the British Journal of Pharmacology demonstrating that the biologically-active metabolite of ketamine, (2R,6R)-hydroxynorketamine (HNK) shows potential for possibly addressing multiple aspects of opioid use disorder. In this comprehensive investigation, we established several mouse models that mimic some of the human endophenotypes of opioid dependence and […]
Upcoming Seminar: “Decoding ketamine: Neurobiological mechanisms underlying its rapid antidepressant efficacy”
We are pleased to announce an upcoming seminar by Dr. Zanos, the Director of the Translational Neuropharmacology Lab at the Center for Applied Neuroscience & Department of Psychology of the University of Cyprus. In this seminar, Dr. Zanos will discuss how unlike traditional monoamine-based antidepressants that require weeks to exert effects, ketamine alleviates depression within […]
Psychedelics as promising treatments for psychiatric disorders: Dr. Zanos’ article in Cyprus press
Dr. Panos Zanos, head of the Zanos Lab at the University of Cyprus, recently published an article in the Cyprus press, highlighting the therapeutic potential of psychedelics for treating psychiatric disorders. The article explores how substances like psilocybin, MDMA (ecstasy), and ketamine are emerging as innovative treatments for conditions such as depression and PTSD, particularly […]
Dr. Andrea Georgiou delivers expert talk on smoking addiction biomarkers at KES College
We’re excited to announce that Dr. Andrea Georgiou, head of the Genetics Epidemiology Unit within the Zanos lab was invited to give a talk on her research on biomarkers associated with smoking addiction at KES College in Cyprus. The presentation focused on investigating biological indicators related to smoking dependence in the Cypriot population. Dr. Georgiou brings […]
Dr. Zanos was invited to discuss groundbreaking ketamine clinical trial on Cyprus Broadcasting Corporation
We are pleased to announce that Dr. Zanos was recently invited to appear on the Cyprus Broadcasting Corporation (RIK) to discuss our laboratory’s groundbreaking clinical trial investigating ketamine as a treatment for opioid use disorder (OUD). This pioneering study—the first of its kind in Cyprus—is being conducted at the “GEFYRA” (BRIDGE) Substitute Substance Unit in […]
New special issue led by our lab: Climate-Driven Effects on the Human Microbiome and Public Health
We’re excited to announce that our laboratory is leading a special issue in Microorganisms journal focusing on the intersection of climate change and the human microbiome. Dr. Zanos and Dr. Onisiforou are serving as Guest Editors for this initiative. Our special issue aims to explore how environmental changes affect human-associated microbial communities and their subsequent […]
The Zanos Lab welcomes our new Marie Skłodowska-Curie (Onisilos co-fund) fellow, Dr. Polymnia Louka!
We are excited to welcome Dr. Polymnia Louka to the Translational Neuropharmacology Lab as an ONISILOS Marie Skłodowska-Curie Fellow. Her research focuses on the effects of ketamine’s enantiomers and active metabolites on depression-induced bone impairment, aiming to uncover novel therapeutic interventions at the intersection of neuropharmacology, bone biology, and imaging. Dr. Louka has a diverse […]
Cover story feature: Zanos Lab’s groundbreaking paper on microbial influences in Alzheimer’s Disease
We are delighted to announce that our recent publication on microbial influences in Alzheimer’s disease has been selected for the cover story for Volume 13, Issue 1 (January 2025) of Microorganisms journal. This recognition by the journal highlights the significance and timeliness of our research in challenging traditional paradigms of Alzheimer’s Disease treatment. The cover […]